We have shown that GM‐CSF (sargramostim) is effective in restoring immune homeostasis and clinical improvement in PD patients, and as GM‐CSF preferentially targets myeloid lineages,14 we utilized monocytes‐macrophages as a means to uncover therapeutic‐related biomarkers at the molecular level. The gene discussed is CSF2; the disease is Parkinson disease.